U.S. Markets open in 3 hrs 22 mins

David Green, President and CEO of Harvard Bioscience, Inc. (HBIO), Interviews with The Wall Street Transcript

67 WALL STREET, New York - August 2, 2013 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Cardiac - Health Care - Affordable Care Act - Continued Pricing Pressure - Aging U.S. Population

Companies include: Harvard Bioscience Inc. (HBIO) and many more.

In the following excerpt from the Medical Devices Report, the President and CEO of Harvard Bioscience, Inc. (HBIO) discusses company strategy and the outlook for this vital industry:

TWST: Can you explain the technology behind your InBreath tracheal scaffold and bioreactor system that's been making the news?

Mr. Green: Sure, so let me just take you back a little bit. So the InBreath system is a clinical product. What I'd just described to you is the history of the company, which is in research products, and starting about four years ago, some clinical researchers started to adapt our life science research products for use in clinical research and then ultimately in clinical transplants, and the first product that was used in that way is what we today call InBreath tracheal transplant system. And that is a combination of a synthetic scaffold and a bioreactor, which makes an organ outside the body to transplant, and the first ever regenerated organ transplant, in fact, the first ever regenerated tracheal transplant was done in 2008, and it used that InBreath technology.

That patient is still alive five years postsurgery, where old trachea which was diseased was taken out surgically and replaced with a new one grown in the laboratory. That was five years ago, and mostly recently, just in April of this year, the first surgery of these regenerated tracheal transplants done in the United States was performed. It was performed at Children's Hospital of Illinois and there, a synthetic scaffold plus our bioreactor was used for the first time in a U.S. patient, and that patient was actually a baby girl. She was actually 2.5 years old at the time of the surgery, and she was announced to the world about a month after the surgery, and that announcement made headlines not only across the world but also in The New York Times, and it was on the TODAY Show as well. So yes, you're right, we've been making some news for ourselves just recently.

TWST: What are the most significant trends, developments or changes that you anticipate in the regenerative medicine market over the next few years?

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.